Therapeutic Monitoring of Tacrolimus

Morris RE . New small molecule immunosuppressants for transplantation: Review of essential concepts. J Heart Lung Transplant 1993; 12: 275–86.

European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423–8.

US Multicentre FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110–5.

Denesyuk AI Korpela T Lundell J Sara R Zav'yalov VP . Comparison of conformations of cyclosporin A and macrolide FK506 fragments: Localization of putative binding sites with phosphatase calcineurin. Biochem Biophys Res Commun 1993; 194: 280–6.

Braun W Kallen J Mikol V Walkinshaw MD Wuthrich K. Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB J 1995; 9: 63–72.

Henderson DJ Naya I Bundick RV Smith GM Schmidt JA . Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 productions. Immunology 1991; 73: 316–21.

Johansson A Moller E. Evidence that the immunosuppressive effects of FK506 and cyclosporin are identical. Transplantation 1990; 50: 1001–7.

Liu J Farmer JD Lane WS Friedman J Weissman I Schreiber SL . Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807–15.

McCaffrey PG Perrino BA Soderling TR Rao A. NFATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 1993; 268: 3747–52.

Shaw KT-Y Ho AM Raghavan A Kim J Jain J Park J Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFATI in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205–9.

Shaw J-P Utz PJ Durand DB Toole JJ Emmel EA Crabtree GR . Identification of a putative regulator of early T-cell activation genes. Science 1988; 241: 202–5.

Fruman DA Burakoff SJ Bierer B. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8: 391–400.

Takada K Katayama N Kiriyama A Usuda H. Distribution characteristics of immunosuppressants FK506 and cyclosporin in the blood component. Biopharm Drug Disp 1993; 14: 659–72.

Demetris AJ Fung JJ Todo S McCauley J Jain A Takaya S Conversion of liver allograft recipients from cyclosporin to FK506 immunosuppressive therapy—a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056–62.

Jordan ML Shapiro R Vivas CA Scantlebury VP Rhandhawa P Carrieri G FK506 “rescue” for resistant rejection of renal allografts under primary cyclosporin immunosuppression. Transplantation 1994; 57: 860–5.

Cox KL Lawrence-Miyasaki LS Garcia-Kennedy R Lennette ET Martinez OM Krams SM An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on tacrolimus after liver transplantation. Transplantation 1995; 59: 524–9.

Collins RH . Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. [Letter]. Lancet 1994; 344: 949.

Dumont FJ Staruch MJ Koprak SL Siekerka JJ Lin CS Harrison R The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992, 176: 751–60.

Spector R Park GD Johnson GF Vesell ES . Commentary: Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345–53.

McInnes L. The value of therapeutic drug monitoring to the practising physician—an hypothesis in need of testing. Br J Clin Pharmacol 1989; 27: 281–4.

Aronson JK Hardman M. ABC of monitoring drug therapy: Measuring plasma drug concentrations. BMJ 1992; 305: 1078–80.

Ihara H Shinkuma D Ichikawa Y Nojima M Nagano S Ikoma F. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients—importance of trough level as a practical indicator. Int J Urol 1995; 2: 151–5.

Jain AB Abu-Elmagd K Abdallah H Warty V Fung J Todo S Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993; 33: 606–11.

Jusko WJ Piekoszewiski W Klintmalm GB Shaefer MS Herbert MF Piergies AA Pharmacokinetics of tacrolimus in liver transplant recipients. Clin Pharmacol Ther 1995; 57: 281–90.

Sewing K-Fr. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26: 3267–9.

Jain AB Venkataramanan R Cadoff E Fung JJ Todo S Krajack A Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22: 57–9.

Furukawa H Imventarza O Venkataramanan R Susuki M Zhu Y Warty VS The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation 1992; 53: 722–5.

Warty V Diven W Cadoff E Todo S Starzl T Sanghvi A. FK506: A novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation 1988; 46: 453–5.

Jusko WJ . Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17: 596–601.

Wallemacq PE Firdaous I Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem 1993; 39: 1045–9.

Machida M Takahara S Ishibashi M Hayashi M Sekihara T Yamanaka H. Effect of temperature and hematocrit on plasma concentration of FK506. Transplant Proc 1991; 23: 2753–4.

Christians U Radeke HH Kownatzki R Schiebel HM Schottman R Sewing K-Fr. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem 1991; 24: 271–5.

Christians U Braun F Schmidt M Kosian N Sheibel HM Ernst L Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver graft recipients. Clin Chem 1992; 38: 2025–32.

McDiarmid SV Colonna JO Shaked A Vargas J Ament ME Busuttil RW . Differences in oral FK506 dose requirements between adult and pediatric liver transplant recipients. Transplantation 1993; 55: 1328–32.

Undre N Moller A Stadler P. Clinical Pharmacokinetics of Tacrolimus. München: W. Zuckschwerdt Verlag, 1995: 32–3.

Sattler M Guengerich FP Yun C-H Christians U Sewing K-F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos Biol Fate Chem 1992; 20: 753–61.

Shigara T Matsuda H Nagase K Iwasaki K Yamazaki H Metabolism of FK.506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727–35.

Mieles L Venkataramanan R Yokoyama I Warty VJ Starzl TE . Interaction between FK.506 and clotrimazole in a liver transplant recipient. Transplantaion 1991; 52: 1086–7.

Shapiro R Venkataramanan R Warty V Scantlebury V Rybka W McCauley J FK.506 interaction with danazol. Lancet 1993; 341: 1344–5.

Wolter K Wagner K Philip T Fritschka E. Interaction between FK506 and clarithromycin in renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207–8.

Scheiner PA Mor E Chodoff L Sheldon G. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1994; 57: 1132.

Schaeffer MS Collier D Sorrell MF . Interaction between FK506 and erythomycin. Ann Pharmacother 1994; 28: 280–1.

Manez R Martin M Venkataramanan R Silverman D Jain A Warty V Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521–35.

Furlan V Perello L Jacquemin E Debray D Taburet AM , Interactions between FK506 and rifampicin or erythromycin in paediatric liver transplant recipients. Transplantation 1995; 59: 1216–7.

Lake KD Canafax DM . Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrob Chemother 1995; 36 (suppl B): 11–22.

Iwasaki K Matsuda H Nagase K Shiraga T Tokuma Y Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82: 209–16.

Vathsala A Goto S. Yoshimura N, Stepkowski S, Chou T-C, Kahlan D. The immunosuppressive antagonism of low doses of FK506 and cyclosporin. Transplantation 1991; 52: 121–8.

Tamura K Kobayashi M Hashimoto K Kojima K Nagase K Iwasaki K A highly sensitive method to assay FK-506 in plasma. Transplant Proc 1987; 19 (suppl 6): 23–9.

Cadoff EM Venkataramanan R Krajack A Jain AS Fung JJ Todo S Assay of FK506 in plasma. Transplant Proc 1990; 22 (Suppl 1): 50–1.

Warty V Zuckerman S Venkataramanan R Lever J Fung J Starzl T. FK506 measurement: Comparison of different analytical measurements. Ther Drug Monit 1993: 15: 204–8.

Jusko WJ D'Ambrosio R. Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 1991; 23: 2732–5.

D'Ambrosio R Girzaitis N Jusko WJ . Validation and quality assurance program for monitoring tacrolimus (FK506) concentrations in plasma and whole blood. Ther Drug Monit 1993: 15: 414–26.

Grenier FC Luczkiw J Bergmann M Lunetta S Morrison M Blonski D A whole blood FK.506 assay for the IMx^ch analyzer. Transplant Proc 1991; 23: 2748–9.

D'Ambrosio R Girzaitis N Jusko WJ . Multi-centre comparison of tacrolimus (FK506) whole blood concentrations as measured by the Abbott IMx analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit 1994; 16: 287–92.

Holt DW Johnston A Roberts N Tredger JM Trull AK . Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists' task force. Ann Clin Biochem 1994; 31: 420–46.

Wallemacq PE Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical and analytical aspects. Clin Chem 1993; 39: 2219–28.

Winkler M Christians U Baumann J Gonschior AK Wonigkeit K Pichlmayr R. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart and liver transplantation. Ther Drug Monit 1996; 18: 640–6.

MacFarlane G Scheller D Ersfeld D Jensen T Jevans A Wong P-Y A simplified whole blood ELISA [ProTrac-II] for tacrolimus (FK506) using a proteolytic extraction in place of organic solvents. Ther Drug Monit 1996; 18: 698–705.

Grenier F Koshy T Luczkiw J Sul M Vannest R. The new IMx tacrolimus II assay. In: IMx Tacrolimus II: Clinical Utility and Monitoring. Wiesbaden, Germany: Abbott Diagnostics Educational Services, Abbott Diagnostics, 1997: 6–7.

Tredger M Gilkes CD Gonde CE . Therapeutic monitoring of tacrolimus (FK560) with the first and second generation MEIA assays: Performance and results in four patient populations. Ther Drug Monit (in press).

Venkataramanan R Warty VS Zemaitis MA Sanghvi AT Burckart GJ Seltman H Bipoharmaceutical aspects of FK-560. Transplant Proc 1987; 19 (suppl 6): 30–5.

Friob MC Hassoun A Lattine D Lnoest G Otte JB Wallemacq PE . A combined HPLC-ELISA evaluation of FK506 in transplant patients. Transplant Proc 1991; 23: 2750–2.

Warty V Zuckerman S Venkataramanan R Lever J Chao J McKaverey T Tacrolimus analysis: A comparison of different methods and matrices. Ther Drug Monit 1995; 17: 159–67.

Takada K Oh-Haski M Yoshikawa H Muranishi S. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. J Chromatogr 1990: 530: 212–8.

Taylor PJ Jones A Balderson GA Lynch SV . Norris RLG, Pond SM. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 1996; 42: 279–85.

Ingels SC Koenig J Scott MG . Stability of FK506 (tacrolimus) in whole-blood specimens. Clin Chem 1995; 41: 1320–1.

Erden E Warty V Magnone M Shapiro R Demetris J Randhawa P. Plasma FK506 levels in patients with histologically documented renal allograft rejection. Transplantation 1994; 58: 397–8.

Japanese FK506 Study Group. Morphological characteristics of renal allografts under FK506 therapy: Is graft biopsy available to reveal the morphological findings corresponding with FK506 nephropathy? Transplant Proc 1993; 25: 624.

Backman L Nicar M Levy M Distant D Eisenstein C Renard T FK506 trough levels in whole blood and plasma in liver transplant recipients: Correlation with clinical events and side effects. Transplantation 1994; 57: 519–25.

Sigal NH Dumont FJ . Cyclosporin A. FK-506, and rapamycin: Pharmacological probes of lymphocyte signal transduction. Annu Rev Immunol 1991; 10: 519–60.

Beysens AJ Wijnen RMH Beuman GH van de Heyden J. Kootstra G van As H . FK506: Monitoring in plasma or in whole blood? Transplant Proc 1991; 23: 2745.

Ueda M Uemoto S Inomata Y Okajima H Hashida T Tanaka K A proposal of FK506 optimal dosing in living related liver transplantations. Transplantation 1995; 60: 258–64.

Esquivel CO So SK McDiarmid SV Andrews WS Colombani PM . Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. Transplantation 1996; 61: 847–8.

Cacciarelli TV Esquivel CO Cox KL Hayashi M Berquist WE Concepcion W Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61: 1188–92.

Lieberman R Nelson A. Dose-response and concentration-response relationships: Clinical and regulatory perspectives. Ther Drug Monit 1993; 15: 498–502.

Kershner RP Fitzsimmons WE . Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920–6.

Gonschior A-K Christians U Winkler M Linck A Baumann J Sewing K-F , Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996; 42: 1426–32.

Gonschior A-K Christians U Braun F Winkler M Linck A Baumann J Measurement of blood concentrations of FK560 (tacrolimus) and its metabolites in seven liver graft recipients after the first dose by HPLC-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol 1994; 38: 567–71.

Iwasaki K Shigara T Nagase K Tozuka Z Noda K Sakuma S Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos Biol Fate Chem 1993; 21: 971–7.

Iwasaki K Shigara T Matsuda H Nagase K Tokuma Y Hata T Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites at multiple sites of FK506. Drug Metab Dispos Biol Fate Chem 1995; 23: 28–34.

Winkler M Christians U Stoll K Pichlmayr R. Comparison of different assays for the quantification of FK506 levels in blood or plasma. Ther Drug Monit 1994; 16: 281–6.

Facey S Trull A Tan K Friend P Calne R. Monitoring FK506 after liver transplantation. J Hepatol 1992; 16 (Suppl 1): S44.

Winkler M. Practical aspects of tacrolimus immunosuppression in patients after solid organ transplantation. In: Tacrolimus—Clinical Utility and Monitoring. Witsbaden, Germany: Abbott Diagnostic Educational Services, Abbott Diagnostics, 1995: 18–20.

Abu-Elmagd K Fung JF Alessiani M Jain A Venkataramanan R Warty VS The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52: 71–7.

Shirakata Y Kobayashi M Ohtsuka K Sugano M Terajima H Ikai I Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. Transplantation 1995; 60: 1582–7.

Erden E Warty V Magnone M Shapiro R Demetris J Randhawa P. Plasma FK506 levels in patients with histologically documented renal allograft rejection. Transplantation 1994; 58: 397–8.

Sandborn WJ Lawson GM Cody TJ Porayko MK Hay JE Gores GJ Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology 1995; 21: 70–6.

Schreiber SL . Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 151: 283–7.

Warty V Venkataramanan R Zendehrouh P McKaveney T Chao J Todo S Distribution of FK506 in plasma lipoproteins in transplant patients. Transplant Proc 1991; 23: 954–5.

Bakhtiar R Stearns RA . Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 1995; 9: 240–4.

Undre N Moller A . FK 506 European Study Group. Pharmacokinetic interpretation of FK506 levels in blood and plasma during a European randomised study in primary liver transplant patients. Transpl Int 1994; 7: 15.

Lewis GP Jusko WJ Burke C Graves L. Prednisolone side-effects and serum-protein levels. Levels 1971; ii: 778–80.

Boston Collaborative Drug Surveillance Program (BCDSP). Diphenylhydantoin side-effects and serum albumin levels. Clin Pharmacol Ther 1973; 14: 529.

Greenblatt DJ Koch-Weser J. Clinical toxicity of chloridazepoxide and diazepam in relation to serum albumin concentration: A report from BCDSP. Eur J Clin Pharmacol 1974; 7: 259.

Blaschke TF Meffin PJ Melmon KL Rowland M. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 1975; 17: 685.

Piafsky KM Sitar DS Rangno RE Ogilvie RI . Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977; 296: 1495.

Jain AB Venkataramanan R Cadoff E Fung J Todo S Krajak A Effect of hepatic dysfunction and T-tube clamping on FK506 pharmacokinetics. Transplant Proc 1990; 22: 57.

Mueller AR Platz K-P Bechstein WO Schattenfroh N Stoltenbur-Didinger G Blumhardt F Neurotoxicity after orthotopic liver transplantation. Transplantation 1994; 58: 155.

Dawson TM Steiner JP Lyons WE Fotuhi M Blue M Snyder SH . The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: Relationship with calcineurin. Neuroscience 1994; 62: 569–80.

Zeevi A Eiras G Kaufman C Alessiani M Demetris AJ Abu-Elmagd K Correlation between bioassayed plasma levels of FK506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc 1991; 23: 1406–8.

Burres NS Premachandran U Hoselton S Cwik D Hochlowski JE Ye Q Simple aromatics identified with a NFAT-lacZ transcription assay for the detection of immunosuppressants. J Antibiot 1995; 48: 380–6.

Donnelly JG Soldin SJ . Radioreceptor assays for the measurement of cyclosporin activity: A preliminary report. Ther Drug Monit 1989; 11: 696–700.

Lorber MI Paul K Harding RE Handschumacher RE Marks WH . Cyclophilin binding: A receptor-mediated approach to monitoring cyclosporin immunosuppressive activity following organ transplantation. Transplant Proc 1990; 22: 1240–4.

Murthy JN Chen Y Warty VS Venkataramanan R Donnelly JG Zeevi A Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. Clin Chem 1992; 38: 1307–10.

Russell RL Donnelly JG Palaszynski EW Chan MM Soldin SJ . A preliminary study to evaluate an in vitro assay for determining patient whole blood immunosuppressive cyclosporin A and metabolite activity: Comparison with cytosolic binding assays using cyclophilin or a 50-kilodalton binding protein, and the Abbott TDx cyclosporin A parent, and metabolites assays. Ther Drug Monit 1991; 13: 32–6.

Asami M Kuno T Mukai H Tanaka C. Detection of the FK506-FKBP-calcineurin complex by simple binding assay. Biochem Biophys Res Commun 1993; 192: 1388–94.

Tamura K Fujimura T Iwasaki K Sakuma S Nakamura K Shimomura K Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Commun 1994; 202: 437–43.

Soldin SJ Murthy JN Donnelly JG Chen Y Goodyear N. Immunophilin receptors for immunosuppressive drugs. Ther Drug Monit 1993; 15: 468–71.

Su Q Weber L Le Hir M Zenke G Ryffel B. Nephrotoxicity of cyclosporin A and FK506: Inhibition of calcineurin phosphatase. Renal Physiol Biochem 1995; 18: 128–39.

Bierer BE . Cyclosporin A, FK506, and rapamycin: Binding to immunophilins and biological action. Chem Immunol 1994; 59: 128–55.

Baughman G Wiederrecht GJ Campbell NF Martin MM Bourgeois S. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 1995; 15: 4395–402.